Barclays Maintains Overweight on Tenet Healthcare, Raises Price Target to $271

Benzinga Newsdesk www.benzinga.com Positive 85.2%

Neg 0% Neu 0% Pos 85.2%

Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:THC) with a Overweight and raises the price target from $240 to $271.